C4X Discovery Holdings inks $402m deal with AstraZeneca
C4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
EpiEndo Pharmaceuticals pushes COPD candidate
/in News/by Thomas GabrielczykEpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395
Neotiv GmbH closes 10m seed financing
/in News/by Thomas GabrielczykGerman Neotiv GmbH hat closed a 10m seed financing to speed-up product launch of its early diagnosis app for Alzheimer’s disease
Fungal skin replaces plastics in electronics
/in News/by Thomas GabrielczykResearchers from the University of Linz (Austria) report progress on the way to make electronic devices more sustainable and more recyclable
Memo Therapeutics and Ono Pharmaceutical enter partnership
/in News/by Thomas GabrielczykAntibody developer Memo Therapeutics AG has snaged a R&D partnership with Ono Pharmaceutical Co. Ltd in the immuno-oncology field.
EU Health Union ignoring cardiology
/in News/by Thomas GabrielczykThe European Council has adopted three regulations aimed at improving pandemic preparedness, which together with two other pillars complete the EU Health Union.
Healthcare investments in Catalonia at record high
/in News/by Thomas GabrielczykCatalonia’s healthcare start-ups raised 238m in 2021, a new record and 4% up from 2020. Four fifth (83%) of VC came from international investors.
Audi and Krajete create CO2 air capture plant
/in News/by Thomas GabrielczykAutomotive company Audi AG and gas fermentation specialist Krajete GmbH are building a highly effective industrial-scale CO2 Direct Air Capturing plant in Linz.
Solar Foods protein from carbon dioxide gets authorisation
/in News/by Thomas GabrielczykFinnish Solar Foods Ltd has got the first ever novel food authorisation for its microbially-produced protein powder Solein.
Bone Therapeutics merges with Medsenic and changes name
/in News/by Thomas GabrielczykBone Therapeutics has merged with French inflammatory/autoimmune company Medsenic in a 40m deal and changed its name into BioSenic.